Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved the prefilled insulin pens NovoLog® (insulin aspart [rDNA origin] injection) FlexTouch® and Levemir® (insulin detemir [rDNA origin] injection) FlexTouch®. FlexTouch® is a new prefilled insulin delivery system from Novo Nordisk.
When a dose is dialed with traditional prefilled pens, the push button extends, and at larger doses this can present challenges for the patient. The unique dosing mechanism of FlexTouch® ensures the push-button does not extend at any dose and allows insulin to be administered by pressing the low dose force button.
"Novo Nordisk is committed to continuously introducing new solutions that can improve the lives of people with diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. "This approval marks another advancement in insulin delivery and an important milestone for Novo Nordisk."
Novo Nordisk plans to make NovoLog® FlexTouch® and Levemir® FlexTouch® available in the U.S. within the next year. FlexTouch® was approved by the European Commission in July 2011 and has launched in several countries, including the United Kingdom, Canada, Denmark and Japan.
For more information visit www.novonordisk-us.com.